{
    "id": 21451,
    "fullName": "CDK2 dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "CDK2 dec exp indicates decreased expression of the Cdk2 protein. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1017,
        "geneSymbol": "CDK2",
        "terms": [
            "CDK2",
            "CDKN2",
            "p33(CDK2)"
        ]
    },
    "variant": "dec exp",
    "createDate": "04/20/2016",
    "updateDate": "08/24/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5868,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CDK2 knockdown with siRNA sensitized ER-positive breast cancer cells harboring PIK3CA mutations to Ibrance (palbociclib) induced growth inhibition in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 21973,
                "profileName": "CDK2 dec exp ESR1 pos PIK3CA mut"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 21972,
            "profileName": "CDK2 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21973,
            "profileName": "CDK2 dec exp ESR1 pos PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}